四价人乳头瘤病毒疫苗在中国9至26岁女性中的免疫原性与安全性:一项3期开放标签免疫桥接研究
该3期开放标签免疫桥接研究纳入766名9-26岁中国女性,比较9-19岁女孩与20-26岁年轻女性接种三剂四价HPV疫苗后的免疫原性与安全性。结果显示9-19岁组抗体GMT非劣效于20-26岁组,两组均全部 seroconvert,疫苗总体耐受良好,无疫苗相关严重不良事件。
要点
- 9-19岁女孩接种三剂qHPV疫苗后抗体GMT非劣效于20-26岁女性。
- 疫苗总体耐受良好,未发生疫苗相关严重不良事件。
核心结论
- 中国9-19岁女孩接种三剂qHPV疫苗的抗体应答非劣效于20-26岁年轻女性,且疫苗总体耐受良好。
研究设计与样本
- 3期、开放标签、免疫桥接研究(NCT03493542),共纳入766名9-26岁中国女性,按年龄分为9-19岁组(383人)和20-26岁组(383人),均接种三剂qHPV疫苗(第1天、第2月、第6月)。
主要发现
- 第7个月时,符合方案免疫原性人群中两组所有受试者对HPV6/11/16/18均 seroconvert。
- 9-19岁组第7个月抗HPV6/11/16/18抗体GMT非劣效于20-26岁组。
- 9-19岁组注射部位不良事件和全身不良事件报告率分别为36.6%和49.3%,20-26岁组分别为40.7%和54.8%。
- 未发生疫苗相关严重不良事件,无因不良事件终止接种者,无死亡报告。
关键数值与推荐
- 主要免疫原性终点为第7个月抗HPV6/11/16/18抗体GMT非劣效于20-26岁组。
- 所有受试者在第7个月对每个疫苗HPV型别均达到 seroconversion。
- 安全性终点包括接种后30天内注射部位和全身不良事件,以及研究期间任何时间的严重不良事件。
临床怎么用
- 研究结果支持qHPV疫苗在中国9-19岁女孩中使用的免疫原性非劣效于20-26岁女性,且安全性良好。
局限性
- 本研究为开放标签设计,未设安慰剂对照。
- 报告数据截至第7个月,长期抗体持久性需待第60个月结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) vaccine was approved for use in Chinese women aged 20-45 years in 2017. This Phase 3, open-label study (NCT03493542) aimed to assess immunogenicity and safety of the qHPV vaccine in Chinese girls aged 9-19 years versus Chinese young women aged 20-26 years; we report results from Day 1 through Month 7. The study will continue through Month 60 to assess antibody persistence in Chinese girls aged 9-19 years. METHODS: Participants aged 9-26 years received three doses of the qHPV vaccine (Day 1, Month 2, Month 6). Geometric mean titers (GMTs) and seroconversion percentages for anti-HPV6/11/16/18 antibodies were determined by competitive Luminex immunoassay (cLIA) in serum samples obtained on Day 1 and at Month 7. Injection-site adverse events (AEs) and systemic AEs within 30 days post-vaccination, and serious AEs (SAEs) occurring at any time during the study, were recorded. RESULTS: In total, 766 participants (383 aged 9-19 years; 383 aged 20-26 years) were enrolled and received ≥1 vaccine dose. All participants in the per-protocol immunogenicity population of both age groups seroconverted to each of the vaccine HPV types at Month 7. Anti-HPV6/11/16/18 antibody GMTs at Month 7 in participants aged 9-19 years were non-inferior to those in participants aged 20-26 years. Injection-site AEs and systemic AEs were reported by 36.6% and 49.3% of 9-19-year-olds, and 40.7% and 54.8% of 20-26-year-olds, respectively. There were no vaccine-related SAEs. No participants discontinued the vaccine due to an AE and no deaths were reported. CONCLUSION: Antibody responses induced by the 3-dose qHPV vaccination regimen in Chinese girls aged 9-19 years were non-inferior to those in Chinese young women aged 20-26 years. The vaccine was generally well tolerated in the study population. ClinicalTrials.gov Identifier: NCT03493542.
引用
- Huang Z, He J, Su J, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study. Vaccine. 2020. PMID: 33239228. doi:10.1016/j.vaccine.2020.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。